NeuroVision has announced completion of a nonexclusive license agreement with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that will significantly expand the companies’ collaboration.
Dr. Black discussing the challenges of Alzheimer’s and some potential solutions, at Google’s Solve for X event.
Google Solve For X
NeuroVision developed a novel retinal imaging technology, which is currently being utilized in a number of clinical trials globally. The test provides clinicians with a simple, objective retinal imaging test that enables detection of amyloid beta plaques and monitoring of patients over time.
Retinal Imaging Test
Animal models, human cadaver studies, and human clinical trials confirm the presence of amyloid beta plaque in the human retina. Ongoing clinical trials demonstrate separation of Alzheimer’s and MCI patients from healthy controls.
Alzheimer’s disease and other dementias will grow each year as the size and proportion of the population aged 65 and older continue to increase. By 2050, the number of people with Alzheimer’s disease is estimated to increase 300% and reach 131 million.